Rick,
additional speculation: oncology.healthace.com
sales
Incyte: Undisclosed Pipeline Compound (INCB040093) Enters Clinic for B-Cell Malignancies +/- Rituxan; ‘093 Could Be a PI3K Delta Inhibitor
Our checks of clinicaltrials.gov have revealed that one of Incyte's 'mystery' pipeline compounds, INCB040093, whose identity and target has not been disclosed, has now officially entered the clinic in a phase I study of 50 patients with previously-treated B-cell malignancies +/Rituxan. According to the clinicaltrials.gov listing, data is expected by end-2014.
Recall that we have been following this undisclosed compound since last year, when grants we found online suggested that it was teed up for a B-cell malignancy study. At that time, we suspected the agent was likely a PI3K inhibitor, but noted that it might also be an FGFR3 inhibitor.
Based on the company's patent filings since then, as well as an additional reference we found from one of the participating centers doing genomic correlative analyses for the agent, we continue to believe '093 is most likely to be a PI3Kdelta inhibitor.
Although this compound remains early, PI3K is a target that has attracted considerable attention of late in the heme/onc space. With only a few other PI3K inhibitors geared for hematologic malignancies in the clinic, including those from Gilead and Infinity, we believe revelation of this new Incyte program highlights their pipeline depth and could add a new dimension to the Incyte story. Though we remain neutral on Incyte, if '093 is indeed a PI3K inhibitor, we believe its entry into the clinic is a positive development. We expect the company may report more details on the new compound on their earnings call next week.
Source: Wells Fargo Securities/Abrahams, July 24, 2013
Oncology Indication: Hematologic
Keyword: Clinical Trials/Pipeline |
